77 related articles for article (PubMed ID: 4904576)
1. [Trial of allogenic bone marrow graft in rats after conditioning with cyclophosphamide].
Kolar V; Kolarova M
Rev Fr Etud Clin Biol; 1969 Oct; 14(8):780-2. PubMed ID: 4904576
[No Abstract] [Full Text] [Related]
2. Renal transplantation in the inbred rat. 18. Effect of cyclophosphamide on acute rejection and long survival of recipients.
Kawabe K; Guttmann RD; Levin B; Merrill JP; Lindquist RR
Transplantation; 1972 Jan; 13(1):21-6. PubMed ID: 4550343
[No Abstract] [Full Text] [Related]
3. [Isogeneic bone marrow transplantation in rats previously treated with cyclophosphamide (preliminary report)].
Hernández P; Carmena A; Callejas J
Rev Clin Esp; 1972 Mar; 124(6):587-90. PubMed ID: 4602405
[No Abstract] [Full Text] [Related]
4. [Isogenic bone marrow transplantation using fresh and preserved bone marrow in rats made aplastic with cyclophosphamide].
Hernańdez P; Callejas J; Carmena A
Sangre (Barc); 1972; 17(1):53-8. PubMed ID: 4552727
[No Abstract] [Full Text] [Related]
5. [Effect of cyclophosphamide and other homologous oxazaphosphorine-2-oxides on transplantation-immunologic reactions].
Müller-Ruchholtz W
Arzneimittelforschung; 1974 Aug; 24(8):1160-7. PubMed ID: 4370872
[No Abstract] [Full Text] [Related]
6. The rhesus monkey as a preclinical model for bone marrow transplantation.
van Bekkum DW
Transplant Proc; 1978 Mar; 10(1):105-11. PubMed ID: 416528
[No Abstract] [Full Text] [Related]
7. Cyclophosphamide. Drug interactions and bone marrow transplantation.
Kovacs K; Steinberg AD
Transplantation; 1972 Mar; 13(3):316-21. PubMed ID: 4553733
[No Abstract] [Full Text] [Related]
8. Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan.
Kim SE; Lee JH; Choi SJ; Lee JH; Ryu SG; Lee KH
Haematologica; 2005 Feb; 90(2):285-6. PubMed ID: 15710597
[TBL] [Abstract][Full Text] [Related]
9. Conditioning with cyclophosphamide/antithymocyte globulin for allogeneic bone marrow transplantation from HLA-matched siblings in children with severe aplastic anemia.
Azuma E; Kojima S; Kato K; Matsuyama T; Yamada Y; Kondo N; Sawada H; Hanada M; Shibata T; Tabata N; Watanabe M; Shimono Y; Deguchi T; Umemoto M; Higashikawa M; Kawasaki H; Komada Y; Sakurai M
Bone Marrow Transplant; 1997 Jun; 19(11):1085-7. PubMed ID: 9193750
[TBL] [Abstract][Full Text] [Related]
10. Host repopulation of endothelium.
Williams GM; Krajewski CA; Dagher FJ; ter Haar AM; Roth JA; Santos GW
Transplant Proc; 1971 Mar; 3(1):869-72. PubMed ID: 4937983
[No Abstract] [Full Text] [Related]
11. Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice.
Nilsson C; Forsman J; Hassan Z; Abedi-Valugerdi M; O'Connor C; Concha H; Jansson M; Hassan M
Exp Hematol; 2005 Mar; 33(3):380-7. PubMed ID: 15730862
[TBL] [Abstract][Full Text] [Related]
12. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
Prigozhina TB; Elkin G; Khitrin S; Slavin S
Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
[TBL] [Abstract][Full Text] [Related]
13. Role of passenger leukocytes in the rejection of renal allografts.
Bastien E; Holter A; Garrick T; Elkins W; Stuart F
Surg Forum; 1970; 21():256-8. PubMed ID: 4936979
[No Abstract] [Full Text] [Related]
14. Graft failure after bone marrow transplantation from unrelated donors using busulphan and cyclophosphamide for conditioning.
Mehta J; Powles RL; Mitchell P; Rege K; De Lord C; Treleaven J
Bone Marrow Transplant; 1994 May; 13(5):583-7. PubMed ID: 8054911
[TBL] [Abstract][Full Text] [Related]
15. Osteogenesis and revitalization in experimental marrow depression by an allogenic marrow transfer vehicle.
Amler MH
Exp Med Surg; 1969; 27(3):316-24. PubMed ID: 4909026
[No Abstract] [Full Text] [Related]
16. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow transplantation in 65 patients with severe aplastic anemia.
Gluckman E; Devergie A; Gerotta I; Hors J; Sasportes M; Boiron M; Bernard J
Bull Cancer; 1981; 68(1):74-7. PubMed ID: 7013871
[TBL] [Abstract][Full Text] [Related]
18. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
[TBL] [Abstract][Full Text] [Related]
19. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM
Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
